NIH Director Francis Collins awarded Leadership in Personalized Medicine Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FRANCIS COLLINS, director of the NIH, was awarded the Leadership in Personalized Medicine Award by the Personalized Medicine Coalition. He will be presented the award during the Personalized Medicine Conference at Harvard Medical School Nov. 19.

In his letter nominating Collins for the award, Harvard Medical School professor Raju Kucherlapati, noted that Collins “has made sustained and critical contributions for the establishment of personalized medicine.”

Collins earned national recognition in 1989, more than a decade before the complete sequencing of the human genome, for his team’s discovery of the gene responsible for cystic fibrosis. He then served as the director of the National Human Genome Research Institute, where he was the overall project manager of the international Human Genome Project, which produced a complete map of the human genome in 2003.

He also played a key role in the passage of the Genetic Information Nondiscrimination Act in 2008, which has helped to ensure that the insights from his extraordinary achievements and those of many others are not used for discriminatory purposes.

President Barack Obama nominated him as NIH director in 2009, proclaiming that his work had already “changed the very ways we consider our health and examine disease.” As director, Collins’ advocacy helped shape the Precision Medicine Initiative, which was announced earlier this year as part of the president’s budget proposal for fiscal year 2016.

“I see a day in the not too distant future when every person will have his or her genome sequenced and other important data collected as a routine part of medical care with individualized strategies developed for diagnosing, treating and preventing their disease,” said Collins. “I know that the PMC shares this vision and I am truly honored to receive this award from an organization that continues to pursue the vision with such great passion.”

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login